Literature DB >> 31931086

Histologic comparison of tumor necrosis factor-α inhibitor-induced psoriasis and psoriasis vulgaris.

Jeffrey Zhu Hu1, Steven D Billings2, Di Yan3, Anthony Patrick Fernandez4.   

Abstract

BACKGROUND: Tumor necrosis factor-α inhibitor (TNFi)-induced psoriasis is a paradoxic reaction characterized by the development of a psoriasiform rash that mimics idiopathic psoriasis subtypes both clinically and histologically. Few studies have investigated the histologic features of TNFi-induced psoriasis skin lesions, and most of these are limited by inclusion of few specimens.
OBJECTIVE: We aimed to characterize histologic features of TNFi-induced psoriasis and identify histologic differences between TNFi-induced psoriasis and idiopathic psoriasis.
METHODS: We characterized 60 biopsy specimens obtained from 47 unique patients at a single tertiary care referral center between 2004 and 2016 who developed TNFi-induced psoriasis, and we compared histologic features to those of 85 biopsy specimens from a control group of 85 patients with idiopathic psoriasis.
RESULTS: The most common histologic reaction pattern in TNFi-induced psoriasis biopsy specimens was psoriasiform (80.0%). Five histologic parameters were significantly different in TNFi-induced psoriasis biopsy specimens compared with idiopathic psoriasis biopsy specimens: at least 3 dermal eosinophils per histologic section, neutrophils in the stratum corneum, neutrophils in the epidermis, papillary plate thinning, and absence of parakeratosis. LIMITATIONS: Inability to exclude lesion selection bias as a potential reason for some significant histologic differences.
CONCLUSIONS: This study supports the idea that histologic differences exist between TNFi-induced psoriasis and idiopathic psoriasis may help distinguish between these conditions, especially for dermal eosinophil counts of 3 or greater.
Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  TNF-α inhibitor–induced psoriasis; eosinophils; histology; parakeratosis; psoriasis vulgaris

Year:  2020        PMID: 31931086     DOI: 10.1016/j.jaad.2020.01.006

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  6 in total

1.  A Case of Adalimumab-Induced Psoriasiform Dermatitis in an Ankylosing Spondylitis Patient: Unusual Progression after Adalimumab Retreatment.

Authors:  Ji Ha Yoon; Joon Woo Jung; Eun Joo Park; Kwang Joong Kim; Kwang Ho Kim
Journal:  Ann Dermatol       Date:  2022-10       Impact factor: 0.722

Review 2.  Cutaneous Manifestations of Inflammatory Bowel Disease: A Basic Overview.

Authors:  Kyla Pagani; Danitza Lukac; Aashni Bhukhan; Jean S McGee
Journal:  Am J Clin Dermatol       Date:  2022-04-20       Impact factor: 6.233

3.  Mechanism of Huoluo Xiaoling Dan in the Treatment of Psoriasis Based on Network Pharmacology and Molecular Docking.

Authors:  Ke Gong; Wen Guo; Kaiqing Du; Fang Wang; Mengli Li; Jianhui Guo
Journal:  Evid Based Complement Alternat Med       Date:  2022-02-27       Impact factor: 2.629

4.  Interleukin-17E, inducible nitric oxide synthase and arginase1 as new biomarkers in the identification of neutrophilic dermatoses.

Authors:  R Stalder; N Brembilla; C Conrad; N Yawalkar; A Navarini; W H Boehncke; G Kaya
Journal:  Clin Exp Dermatol       Date:  2021-12-17       Impact factor: 4.481

5.  Paradoxical Psoriasis Induced by Anti-TNFα Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers.

Authors:  Agostino Bucalo; Federica Rega; Arianna Zangrilli; Valentina Silvestri; Virginia Valentini; Giorgia Scafetta; Federica Marraffa; Sara Grassi; Elena Rogante; Arianna Piccolo; Salvatore Cucchiara; Franca Viola; Luca Bianchi; Laura Ottini; Antonio Richetta
Journal:  Int J Mol Sci       Date:  2020-10-23       Impact factor: 5.923

Review 6.  Cutaneous Manifestations in Biological-Treated Inflammatory Bowel Disease Patients: A Narrative Review.

Authors:  Jo L W Lambert; Sofie De Schepper; Reinhart Speeckaert
Journal:  J Clin Med       Date:  2021-03-03       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.